Treatment of Anxiety Disorders With Trigeminal Nerve Stimulation

Inclusion Criteria: * Meet DSM5 criteria for panic disorder, social anxiety disorder or generalized anxiety disorder. Exclusion Criteria: * Subjects undergoing cognitive behavioural therapy. * Subjects undergoing pharmacological treatment for an anxiety disorder. * Subjects undergoing pharmacological treatment with antidepressants or benzodiazepines. * Subjects with moderate to severe major depressive disorder based on the PHQ-9 test (score of 15 or above) at baseline. * Moderate to high current suicidality or "suicide likely in near future" or current suicidal behavior disorder. * Concurrent diagnosis of OCD, PTSD, bipolar disorder, schizophrenia, schizoaffective disorder, personality disorders, substance use disorders, intellectual disabilities or dementia. * Subjects diagnosed with neurological diseases including trigeminal neuralgia. * Pregnant or breastfeeding women. * Subjects who are experiencing seizures. * Individuals with implanted VNS or other electrical devices. * Subjects who are already undergoing transcutaneous electrical nerve stimulation. * Consumption of cannabis, any cannabis by-products, illicit drugs, or alcohol above 3 drinks per week. * Consumption of natural health products that may affect anxiety or depression symptoms.